Mark E. Neumann is a journalist who writes for Healio, covering a wide range of topics in the medical field. His articles focus on research studies, clinical trials, and developments in healthcare, with a particular emphasis on kidney disease, organ transplantation, and pharmaceutical advancements.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Mark E. Neumann’s coverage primarily focuses on healthcare and pharmaceutical topics, particularly kidney health and cancer care. His work heavily relies on data citations, indicating a preference for pitches supported by robust data or studies.
Given the extensive use of data in his articles, Mark would likely welcome pitches that present new research findings or clinical insights related to kidney health, cancer treatment, and associated pharmaceutical developments. Sources who can provide expert commentary based on recent scientific studies in these fields may also be well-received.
While Mark's geographic focus is not specified, it's important to note that the topics he covers are of global significance within the medical community. Therefore, relevant information from any location could potentially capture his interest if it contributes to advancements in understanding kidney health and cancer care.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mindy Valcarcel, Mark E. Neumann
Nephrology practices could leave the Kidney Care Choices model for patients with chronic kidney disease because of planned reductions in Medicare payments that are “much larger than anticipated,” according to a nephrology advocacy group.
By: Gina Brockenbrough, Mark E. Neumann
LONG BEACH, Calif. — Patients with heart failure who also experienced mitral regurgitation saw a doubling of their creatinine, according to data presented here.
By: Gina Brockenbrough, Mark E. Neumann
LONG BEACH, Calif. — A patient on dialysis who lost weight after bariatric surgery was able to reduce the number of home hemodialysis sessions from five to four treatments without adverse outcomes, researchers said here.
By: Mark E. Neumann, Gina Brockenbrough
LONG BEACH, Calif. — Researchers reported results from a phase 1b/2a placebo-controlled study of DISC-0974, an anti-hemojuvelin antibody to treat anemia in patients with chronic kidney disease.
By: Gina Brockenbrough, Mark E. Neumann
LONG BEACH, Calif. — Clinicians do not consistently use algorithms for dosing methoxy polyethylene glycol-epoetin beta when treating patients with anemia, presented research shows.
By: Mark E. Neumann, Gina Brockenbrough
Editor's note: Healio | Nephrology News & Issues interviewed John Friedewald, MD, and Roberto Hernandez-Alejandro, MD, about their roles as conference chairpersons and highlights of the agenda for the American Transplant Congress.
By: Gina Brockenbrough, Mark E. Neumann
“Xenotransplantation (XTx) presents a promising clinical alternative to address the current shortage of human organs,” Luz Padilla, MD, MPSH, of
By: Mark E. Neumann, Gina Brockenbrough
Fresenius Medical Care and Outset Medical Inc. have launched separate recalls over concerns that tubing in the dialysis machines they manufacture may be leaching a toxic compound during treatment, according to an FDA notice.
By: Gina Brockenbrough, Mark E. Neumann
Nephrology providers have limited knowledge and experience in offering conservative kidney management to patients who decide to forgo renal replacement therapy, recently published survey results show.
By: Mark E. Neumann, Gina Brockenbrough
Among older adults participating in the Systolic Blood Pressure Intervention Trial, a low eGFR without albuminuria was associated with a higher mortality rate but not with increased risk of cardiovascular events, results showed.
(833) 317-6278 